Humanigen, Inc.: Humanigen Launches Managed Access Program for Lenzilumab
Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called 'cytokine storm,' announced today that lenzilumab is now
Source: finanznachrichten.de